R. Lavend’homme

发表

Molecular mechanisms of mild and moderate hemophilia A

M. de Maeyer, K. Peerlinck, J. Saint-Remy, 2003, Journal of thrombosis and haemostasis : JTH.

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

J. Vermylen, L. Vander Elst, K. Thielemans, 2000, Blood.

Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes

J. Vermylen, M. Hoylaerts, J. Vermylen, 1999, Thrombosis and Haemostasis.

Point mutations scattered in the FVIII C1 and C2 domains reduce FVIII binding to vWF and are associated to mild/moderate hemophilia A

R. Schwaab, J. Vermylen, K. Peerlinck, 1999 .

Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody

R. Dwek, M. Wormald, M. Dewerchin, 2006, Journal of thrombosis and haemostasis : JTH.

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.

J. Vermylen, M. Hoylaerts, T. VandenDriessche, 2000, Blood.

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.

J. Vermylen, M. Hoylaerts, J. Arnout, 1999, Blood.

A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons

P. Verhamme, J. Saint-Remy, M. Jacquemin, 2009, Journal of thrombosis and haemostasis : JTH.

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

J. Vermylen, B. Maillère, K. Peerlinck, 2003, Blood.

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool.

A. Luttun, K. Peerlinck, J. Saint-Remy, 2010, Blood.

Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII

K. Peerlinck, M. Jacquemin, E. Sokal, 2014, Journal of thrombosis and haemostasis : JTH.

FVIII production by human lung microvascular endothelial cells.

C. Kirkpatrick, M. Hermanns, F. Rega, 2006, Blood.

Pro‐haemostatic effect of DDAVP is partially derived through non‐classical (CD14dim /CD16 ++) monocytes residing the spleen

M. Karimi, M. Jacquemin, Hassan Rokni-Zadeh, 2022, Journal of cellular and molecular medicine.

The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG‐Arg301 to be distinguished from hypofibrinogenemia

K. Peerlinck, M. Jacquemin, K. Freson, 2017, International journal of laboratory hematology.

Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease

M. Decramer, W. Janssens, G. Gayan‐Ramirez, 2012, Thorax.

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells

R. d'Oiron, K. Peerlinck, J. Saint-Remy, 2011, Journal of thrombosis and haemostasis : JTH.

Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype

J. Oldenburg, T. Lambert, B. Guillet, 2003 .

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

J. Vermylen, C. Négrier, K. Peerlinck, 2004, Blood.

Deletion of residue Ala2201 in the Factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by Factor VIII inhibitor antibodies

B. Stoddard, J. Vermylen, K. Peerlinck, 2001 .

J. Oldenburg, B. Guillet, A. Rafowicz, 2003 .

Coagulation Factors Accumulate During Normothermic Liver Machine Perfusion Regardless of Donor Type and Severity of Ischemic Injury

P. Friend, R. Ploeg, L. Libbrecht, 2021, Transplantation.

A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor

J. Vermylen, K. Peerlinck, J. Saint-Remy, 1997 .